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TNF superfamily members promote hepatitis C virus entry via
an NF-kB and myosin light chain kinase dependent pathway
N. F. Fletcher,1 A. R. Clark,2 P. Balfe1 and J. A. McKeating1,*†
Abstract
Preventing virally induced liver disease begins with an understanding of the host factors that define susceptibility to
infection. Hepatitis C virus (HCV) is a global health issue, with an estimated 170 million infected individuals at risk of
developing liver disease including fibrosis and hepatocellular carcinoma. The liver is the major reservoir supporting HCV
replication and this hepatocellular tropism is defined by HCV engagement of cellular entry receptors. Hepatocytes are
polarized in vivo and this barrier function limits HCV entry. We previously reported that activated macrophages promote HCV
entry into polarized hepatocytes via a TNF-a-dependent process; however, the underlying mechanism was not defined. In
this study, we show that several TNF superfamily members, including TNF-a, TNF-b, TWEAK and LIGHT, promote HCV entry
via NF-kB-mediated activation of myosin light chain kinase (MLCK) and disruption of tight junctions. These observations
support a model where HCV hijacks an inflammatory immune response to stimulate infection and uncovers a role for NF-kB-
MLCK signalling in maintaining hepatocellular tight junctions.
INTRODUCTION
Hepatitis C virus (HCV) is a global health issue with an esti-
mated 170 million infected individuals worldwide. The virus
infects hepatocytes in the liver and leads to progressive liver
injury, fibrosis and in some cases hepatocellular carcinoma.
Infection is initiated by the viral encoded E1E2 glycopro-
teins interacting with cellular receptors: tetraspanin CD81,
scavenger receptor BI (SR-BI), epidermal growth factor
receptor, the cholesterol absorption regulator Niemann–
Pick disease type C1-like 1 protein, and tight junction pro-
teins claudin-1 and occludin (reviewed in [1, 2]). This
multi-step process of receptor engagement primes a cla-
thrin-dependent endocytic uptake of particles into the liver.
Hepatocytes are polarized and HCV particles entering the
liver encounter their basolateral surface that expresses the
‘viral attachment’ proteins CD81 and SR-BI [3]. We
previously reported the presence of CD81-claudin-1
complexes at the basolateral hepatocellular membrane and
live cell imaging demonstrated HCV-dependent CD81 and
claudin-1 co-endocytosis and fusion with Rab5 expressing
endosomes, supporting a role for this receptor complex in
HCV internalization [4]. In contrast, occludin localizes
almost exclusively to the apical tight junctions, which are
considered inaccessible to virus particles, raising questions
on its role in the viral internalization process [5, 6].
Many viruses infect polarized epithelia during host invasion
and, given the well-recognized function of the epithelium to
restrict macromolecule movement across mucosa, viruses
have evolved diverse strategies to overcome this barrier [7,
8]. HCV is associated with liver inflammation during
chronic infection, and we previously reported that IL-1b
and TNF-a secreted from activated macrophages promote
HCV entry by disrupting hepatocyte tight junctions; how-
ever, the mechanism by which this occurred was undefined
[9]. Here, we demonstrate that the TNF superfamily mem-
bers TNF-a, TNF-b, TWEAK and LIGHT promote HCV
infection through an NF-kB- and myosin light chain kinase
(MLCK)-dependent pathway. These data highlight a role for
HCV exploiting TNF superfamily signalling responses in the
liver to promote viral entry and persistence.
RESULTS
TNF superfamily members promote HCV infection
of polarized hepatocytes
We previously reported that TNF-a promotes HCV entry
into polarized hepatocytes [9]. TNF-a is secreted by a wide
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range of activated immune cells and earlier studies showed
that the pro-viral activity of conditioned media from lipopoly-
saccharide-activate macrophages was only partially inhibited
by neutralizing TNF-a, suggesting additional pro-viral factors
[9]. To investigate the potential for other TNF superfamily
members to promote hepatocellular permissiveness to support
HCV entry, we screened a panel of recombinant human TNF
superfamily members for their effect on HCV pseudoparticle
(HCVpp) infection of polarized HepG2.CD81 cells (Fig. 1a).
In addition to TNF-a, we found that TNF-b, TWEAK and
LIGHT promote HCVpp infection in a dose-dependent man-
ner (Fig. 1b). In contrast, TNF family members TRAIL,
CD40L, FasL and APRIL had no detectable effect on HCVpp
infection despite reports of HepG2 cells expressing their cog-
nate receptors [10–13]. We confirmed that TNF-a, TNF-b,
TWEAK and LIGHT increased native HCV J6/JFH infection
of polarized HepG2 cells and observed a significant increase in
viral RNA 48h post-infection (Fig. 1c).
The hepatocyte-derived HepG2 cell line has provided a valu-
able in vitro model for studying hepatocyte polarity [14]. The
bi-potent hepatocyte progenitor HepaRG clone can be differ-
entiated into mixed cultures of polarized hepatocytes and
cholangiocytes [15], and provide an independent model to
validate our results. Differentiated HepaRG-derived hepato-
cyte-like cells expressed the essential HCV entry factors
CD81, occludin and claudin-1, together with the junctional
protein ZO-1, which localize to bile canalicular (BC)-like
structures (Fig. 2a). Consistent with this pattern of viral recep-
tor expression, differentiated HepaRG cells supported HCVpp
entry that was neutralized with an anti-CD81 antibody,
whereas HCVpp failed to infect the non-differentiated pro-
genitor cells (Fig. 2b). Using HCVpp expressing a GFP
reporter, we could demonstrate that HCVpp entry was
restricted to hepatocyte-like cells, whereas Vesicular Stomatitis
Virus encoded G expressing pseudoparticle (VSV-Gpp)
infected cells with both hepatocyte and cholangiocyte mor-
phology (data not shown). These observations were consistent
with our previous report that primary cholangiocytes were not
permissive for HCV infection [16]. Importantly, TNF-a,
TNF-b, TWEAK and LIGHT increased the permissiveness of
differentiated HepaRG cells to support HCVpp infection
(Fig. 2c). Furthermore, pre-treating differentiated HepaRG
cells with TNF (100 ng ml 1) induced a significant increase in
native HCV RNA levels that was CD81-dependent (Fig. 2d).
Collectively, these data demonstrated that several TNF super-
family members promote HCV entry into polarized
hepatocytes.
TNF superfamily members disrupt tight junction
integrity and promote HCV infection through
activation of NF-kB p65/RelA
To investigate the mechanism by which TNF superfamily
members promote HCV entry, we first assessed their effect
on BC tight junction integrity. The fluorescent dye 5-chlor-
omethylfluorescein diacetate (CMFDA), which binds the
apical transporter multidrug resistance-associated protein 2
(MRP2), enabled real-time imaging of BC structures in dif-
ferentiated HepaRG (Fig. 3a) and HepG2 cells, and
allowed us to measure the effect of cytokines on tight junc-
tion integrity [5]. TNF-a, TNF-b, TWEAK and LIGHT
disrupted tight junction integrity in both model systems
(Fig. 3b), with no detectable effect on cellular viability. Of
note, all cytokine-mediated effects on HepG2 polarity were
reversible and tight junction integrity was restored over a
24 h period after their removal, demonstrating the plastic-
ity of the trafficking pathways regulating tight junction
proteins.
The TNF superfamily are well recognized to activate NF-kB
in a range of cell types and using an NF-kB luciferase
reporter assay we showed that TNF-a, TNF-b, TWEAK
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Fig. 1. TNF superfamily members promote HCV infection of polarized HepG2 cells. (a) HepG2.CD81 cells were polarized for 5 days
and infected with HCVpp in the presence or absence of TNF superfamily members TNF-a, TNF-b, TWEAK, LIGHT, TRAIL, CD40L, FasL
or APRIL at 100 ng ml 1 and incubated for 72 h. Cytokines that promote HCV entry are depicted by light grey bars, cytokines that had
no detectable effect are depicted by black bars and the untreated control (UT) is depicted by a white bar. (b) Polarized HepG2.CD81
cells were treated with an increasing dose of TNF-a, TNF-b, TWEAK or LIGHT and infected with HCVpp for 72 h. (c) TNF-a, TNF-b,
TWEAK and LIGHT (100 ng ml 1) increased cell culture propagated hepatitis C virus (HCVcc) J6/JFH infection of polarized HepG2.CD81
cells, where infection was assessed by qRT (quantitative reverse transcriptase)-PCR quantitation of viral RNA levels after 48 h. Data
are presented as mean infectivity ±SD relative to a UT and are representative of three independent experiments where: ****, P<0.0001;
***, P<0.001.
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Fig. 2. TNF promotes HCV infection of differentiated HepaRG cells. (a) HCV receptor staining of differentiated HepaRG cells show baso-
lateral CD81 and claudin-1 expression. The tight junction proteins occludin and ZO-1 were restricted to apical BC-like structures of
hepatocyte-like cells. Bars, 10 µm. (b) Non-differentiated and differentiated HepaRG cells were infected with HCVpp in the presence or
absence of anti-CD81 2.131 (10 µg ml 1); data is presented as Specific Infectivity (SI) reflecting the mean HCVpp luciferase values rela-
tive to an envelope deficient control pseudoparticle. (c) TNF-a, TNF-b, TWEAK and LIGHT (100 ng ml 1) promote HCVpp infection of dif-
ferentiated HepaRG cells. (d) TNF-a (100 ng ml 1) increased HCVcc J6/JFH infection of differentiated HepaRG cells, where infection
was assessed by qRT-PCR determination of viral RNA levels after 72 h. As a control, anti-CD81 2.131 (10 µg ml 1) neutralized HCV
infection of differentiated cells is shown. Data are presented as mean infectivity ±SD relative to the untreated control (UT) and are rep-
resentative of two independent experiments where: ***, P<0.001; **, P<0.01.
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Fig. 3. TNF superfamily members disrupt tight junctions. (a) Differentiated HepaRG cultures comprised hepatocytes (open arrow) and
cholangiocytes (filled arrow). Magnification, 400. Cultures were treated with the fluorescent dye CMFDA that binds the apical trans-
porter multidrug resistance-associated protein 2 enabling real time imaging of bile canaliculi (green structures). Treating cultures with
CMFDA (30min) identified BC structures. (b) Tight junction integrity of HepG2.CD81 and HepaRG cells was measured by quantifying the
number of BC structures retaining CMFDA following 1 h cytokine treatment (100 ng ml 1) in five independent fields of view at 10
magnification with data expressed relative to untreated (UT) cells. N=3 independent experiments.
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Fig. 4. TNF superfamily members promote HCV entry in an NF-kB- and MLCK-dependent manner. (a) HepG2.CD81 cells expressing an
NF-kB luciferase reporter construct were allowed to polarize for 5 days prior to treating with TNF family members (100 ng ml 1) for
24 h. Luciferase reporter activity is expressed relative to UT cells. (b) Polarized HepG2.CD81 cells expressing NF-kB reporter were
treated with an increasing dose of MLN-4924 (µg ml 1) in the presence of TNF-a (100 ng ml 1). (c) Polarized HepG2.CD81 cells were
treated with the indicated concentrations of MLN-4924 and 100 ng cytokine ml 1, 15min prior to infecting with HCVpp; data is
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and LIGHT activate NF-kB in HepG2 cells (Fig. 4a). MLN-
4924 inhibits the Nedd8-activating enzyme that regulates
cullin-RING ubiquitin ligases [17], and has been reported to
limit canonical and non-canonical NF-kB signalling path-
ways [18, 19]. We used MLN-4924 and RelA shortinterfer-
ing RNA (siRNA) to investigate the role of NF-kB in TNF-
a, TNF-b, TWEAK and LIGHT promoted HCV infection
of polarized hepatocytes. We confirmed that MLN-4924
inhibits TNF-a-induced NF-kB reporter activity in a dose-
dependent manner (Fig. 4b). Furthermore, MLN-4924 abro-
gated the pro-viral activity of TNF superfamily members to
promote HCVpp entry (Fig. 4c). It is noteworthy that
MLN-4924 inhibited basal non-cytokine-mediated HCVpp
infection (Fig. 4c), whereas it had no effect on the permis-
siveness of non-polarized HepG2 or Huh-7 cells to support
HCVpp entry, suggesting a role for NF-kB signalling in
polarized HCV entry. Silencing RelA abrogated the pro-
viral activity of TNF superfamily members for HCVpp
infection (Fig. 4d), demonstrating a role for RelA in TNF-
boosted HCV entry.
TNF superfamily members promote HCV entry in a
MLCK-dependent manner
TNF-a disruption of gastrointestinal and lung epithelial
permeability is dependent on NF-kB activation of MLCK,
which regulates occludin and ZO-1 endocytosis [20–22].
We therefore investigated the role of MLCK in basal and
TNF-mediated HCVpp infection. Silencing MLCK reduced
the pro-viral activity of TNF superfamily members for
HCVpp infection of HepG2.CD81 cells (Fig. 4d).
Similar results were obtained by treating cells with the
MLCK inhibitor, ML7, demonstrating a role for MLCK in
TNF-a-, TNF-b-, TWEAK- and LIGHT-dependent
HCVpp infection of polarized to HepG2 (Fig. 4e). We
noted that ML7 induced a significant reduction of basal
HCVpp infection. Finally, we demonstrated that both ML7
and MLN-4924 treatments abrogated the effects of TNF
superfamily members on HepG2 tight junction integrity
(Fig. 5a). These data confirm that TNF superfamily mem-
bers perturb hepatocellular tight junctions via RelA- and
MLCK-dependent pathways that most likely play an
important role in maintaining hepatocyte polarity.
DISCUSSION
Our study shows a role for various members of the TNF
superfamily to promote HCV infection by activating NF-
kB and MLCK-signalling pathways to reduce hepatocellular
tight junction integrity. We observed similar results with
two polarizing hepatocyte models, the well-established
HepG2 hepatoma cell line and the bi-potent HepaRG pro-
genitor that can differentiate into hepatocytes and cholan-
giocytes [23]. We [9] and others [24, 25] have reported
that HCV can activate macrophages to express TNF-a,
enabling the virus to hijack this pro-inflammatory
responses to promote its own entry. TNF superfamily
members are secreted by activated immune cells, including
lymphocytes, macrophages and Kupffer cells, and are
highly expressed in the inflamed liver [9, 26], providing an
environment that potentiates HCV infection of naive hepa-
tocytes. We previously reported that TNF induced a re-
organization of occludin and ZO-1 from apical BC struc-
tures in HepG2 cells via an undefined mechanism [9].
Using inhibitors and siRNA silencing approaches, we dem-
onstrate a role for NF-kB and MLCK-signalling in TNF-a,
TNF-b, TWEAK and LIGHT enhancement of HCV entry
via their perturbation of tight junction integrity. The obser-
vation that inhibiting NF-kB and MLCK limits HCVpp
infection in the absence of inflammatory mediators high-
lights a role for these signalling pathways in polarized virus
entry (Fig. 5b).
Claudin-1 and occludin play an essential role in defining HCV
entry and it is of interest to note that these proteins were ini-
tially discovered to regulate HCV internalization into non-
polarized human embryonal kidney cells [25, 27]. To date, the
published literature support a model where claudin-1 and
occludin regulation of HCV internalization is independent of
their location at tight junctions [2], raising the question of
how TNF superfamily members potentiate HCV infection.
We reported that HCV interacts with claudin-1-CD81 com-
plexes at the basolateral hepatocellular membrane [3, 4]. At
the present time, there is limited evidence to show that HCV
trafficks to the tight junction, indeed Blaising and colleagues
demonstrated HCV internalization via the basolateral mem-
brane and localization within Rab5-positive intracellular
vesicles [28].
Receptor mobility and lateral diffusion speed in the plasma
membrane can regulate the movement of viruses at the
plasma membrane and can impact on particle internaliza-
tion rate(s) [29, 30]. We previously reported that hepatocyte
polarization limits CD81 mobility via cytoplasmic tail
interactions with the cytoskeleton via Ezin-Radixin-Moesin
proteins [31]. Furthermore, HepG2 cells expressing a C-ter-
minal truncated CD81 mutant supported comparable levels
of HCV entry independent of polarization status, suggesting
that membrane protein dynamics on polarized cells may
limit pathogen attachment and infection. Indeed, our report
showing that TNF-a increased CD81 lateral mobility in
polarized HepG2 cells supports this model [9].
presented as mean infectivity ±SD relative to the UT cells (represented by a dotted line). (d) HepG2.CD81 cells were transfected with
control siRNA (siControl), siRelA or siMLCK for 48 h prior to treating with 100 ng ml 1 of the indicated cytokines and infecting with
HCVpp. Western blots demonstrate knockdown of RelA or MLCK, respectively. (e) Polarized HepG2.CD81 cells were treated with the
MLCK inhibitor, ML7, at the indicated concentrations, together with 100ng cytokine ml 1 for 15min prior to infecting with HCVpp. Data
are presented relative to UT cells. Data are representative of three independent experiments, where: ***, P<0.001; and **, P<0.01. UT,
Untreated control.
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Polarized lung and gut epithelia are well recognized to
restrict the invasion of microbial pathogens, and many
viruses have evolved strategies to modulate the cortical
actin network to promote infection of polarized cells [8].
Adenovirus infection of lung epithelia is potentiated by
macrophage expressed IL-8, which stimulates the apical
expression of an alternate viral receptor CAREx8 to enable
the infection of intact epithelium [32]. Our previous report
that TNF-a promoted the permissivity of polarized
HepG2 cells to support entry of pseudoparticles expressing
Vesicular stomatitis virus (VSV), measles or Lassa virus
glycoproteins is consistent with a role for cytoskeletal
changes associated with cell polarization to alter viral
receptor trafficking [9].
Like all epithelial cells, hepatocytes mediate the flow
of macromolecules via their polarized surface that com-
prises tight junctions and cell–cell adhesions. However,
our understanding of the molecular pathways and
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inflammatory mediators regulating hepatocyte polarity in
health or disease are not well understood [33]. The tight
junction is a dynamic structure, and increasing evidence
from studies of gut and lung epithelia highlight the role of
MLCK in regulating the tight junction [21]. Our study sup-
ports a common pathway for TNF family members to regu-
late hepatocyte polarity via MLCK, as reported for other
epithelial cells. In conclusion, we have demonstrated a role
for TNF superfamily signalling in regulating HCV entry
and persistence.
METHODS
Cell lines and antibodies
HepG2 cells stably expressing CD81 [5] and 293T were propa-
gated in Dulbecco’s Modified Eagle’s medium (DMEM) sup-
plemented with 10% FBS and 1% non-essential amino acids.
HepaRG cells were obtained from Invitrogen and maintained
in Williams E medium supplemented with 10% FBS, 5 µg
insulin ml 1 and 50 µM hydrocortisone. HepaRG cell differ-
entiation was performed over a 4 week period, and the media
supplemented with 2% DMSO for the final 2 weeks of differ-
entiation, as described elsewhere [23]. All cells were main-
tained at 37

C and 5% CO2.
The following primary antibodies were used: anti-CD81
(2.131), anti-claudin-1 mAb (Abnova), anti-claudin-1 poly-
clonal sera and anti-occludin (Invitrogen). Secondary labelled
antibodies, Alexa-488 goat anti-mouse IgG, Alexa-488 goat
anti-rabbit IgG, Alexa-594 goat anti-mouse IgG and Alexa-
594 goat anti-rat IgG were purchased from Invitrogen.
Recombinant human cytokines were obtained from Pepro-
tech, MLN-4924 from Calbiochem and ML7 from Sigma-
Aldrich.
Laser scanning confocal microscopy
HepaRG cells were differentiated and fixed with ice-cold
methanol (claudin-1, occludin) or 3% paraformaldehyde
(CD81) 24 h after seeding. Primary antibodies were applied
for 1 h at room temperature. After washing twice with PBS,
anti-mouse, anti-rabbit or anti-rat Alexa Fluor 488 (Invitro-
gen) secondary antibody was applied for 1 h at room tem-
perature. Cells were counterstained with DAPI (Invitrogen)
for nuclei visualization and mounted with ProLong Gold
antifade (Invitrogen). Cells were viewed by laser-scanning
confocal microscopy on a Zeiss META head confocal
microscope with a 100 oil-immersion objective.
Quantifying tight junction barrier function
To determine the functionality of tight junctions and
whether they restricted paracellular diffusion of solutes
from the BC lumen to the basolateral medium, HepG2 or
HepaRG cells were incubated with 5mM CMFDA (Invitro-
gen) at 37

C for 10min to allow translocation to the BC
lumen. After washing extensively with PBS, the capacity of
BC to retain CMFDA was enumerated using a fluorescence
microscope.
NF-kB reporter assays
HepG2.CD81 cells were transfected with a NF-kB reporter
plasmid expressing a firefly luciferase gene (pNiFty-luc;
Invivogen) and polarized for 5 days. Cells were treated with
TNF superfamily members (100 ng ml 1) for 24 h, lysed
and luciferase activity measured for 10 s in a luminometer
(Lumat LB 9507).
HCVpp genesis and infection
Pseudoviruses were generated by transfecting 293T cells with
plasmids encoding a human immunodeficiency virus provirus
expressing luciferase and HCV strain H77 E1E2 region or a
no envelope control (Env ), as previously reported [34].
Virus-containing media was added to target cells for 8 h,
unbound virus removed and media replaced with DMEM/3%
FBS. At 72 h post-infection, the cells were lysed, luciferase sub-
strate added and luciferase activity measured for 10 s in a
luminometer (Lumat LB 9507). Specific infectivity was calcu-
lated by expressing mean HCVpp luciferase values relative to
the mean Env-pp RLU signal. Cytokines were added to cells at
the same time as pseudovirus, and inhibitors were pre-incu-
bated with cells for 15min prior to the addition of cytokine
and pseudovirus.
Cell culture propagated hepatitis C virus genesis
and infection
HCV SA13/JFH was generated and infection quantified by
real-time PCR detection of viral RNA, as previously
described [9].
RelA and MLCK silencing and Western blotting
HepG2.CD81 cells were transfected with a pool of siRNAs
(Smartpool) directed against RelA or MLCK, or a non-specific
control siRNA (Dharmacon). Forty-eight hours post-transfec-
tion, cells were treated with TNF superfamily members
(100 ng ml 1) and infected with HCVpp. In parallel, cells
were lysed and RelA and MLCK expression measured as pre-
viously described [35] by Western blot using RelA and MLCK
antibodies (Cell Signaling Technology).
Statistical analysis
Results are expressed as the mean ± 1 SD of the mean. Statis-
tical analyses were performed using Students t-test in Prism
4.0 (GraphPad) with a P<0.05 being considered statistically
significant and where required corrected for multiple sam-
pling (Bonferroni).
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